Ipca Laboratories Share Price
Small Cap | Pharmaceuticals and health care | NSE: IPCALAB | BSE: 524494
₹1,445.00 
-52.30 (-3.49 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 1,497.20
High (₹) 1,499.00
Low (₹) 1,418.00
Prev. Close (₹) 1,497.30
Volume 10,362
VWAP (₹) 1,438.13
ROCE (%) 12.44
Industry P/E 43.99
TTM P/E 50.26
P/B Ratio 4.74
Market Cap (₹) Cr.36,658.99
Dividend Yield (%)0.28
EPS (₹) 21.57
ROE7.08%
Sales Growth (%) 23.39
Profit Growth (%)7.58
Day Range
1,499.001,499.00
52 Week Range
1,060.951,757.65
Historical Returns
Returns (6M)
3.76 %
Returns (1Y)
18.83 %
Returns (3Y)
51.25 %
Returns (5Y)
96.95 %
Returns (6M)
3.76 %
Returns (1Y)
18.83 %
Returns (3Y)
51.25 %
Returns (5Y)
96.95 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (16.09%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Company with 16.09% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Growth in Net Profit Margin (QoQ)
- Growth in Annual Net Profit with increasing Profit Margin (YoY)
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
Technicals
Technical Rating
BEARISHRSI 52.33
MFI 68.33
ATR 56.76
Commodity Channel Index -2.81
ROC125 4.21
ROC21 -4.63
Williams %R -62.04
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,490.36 | 1,535.18 | 1,571.36 | 1,454.18 | 1,409.36 | 1,373.18 | 1,328.36 |
| Week Ago | 1,505.86 | 1,549.93 | 1,580.86 | 1,474.93 | 1,430.86 | 1,399.93 | 1,355.86 |
| Month Ago | 1,570.45 | 1,597.45 | 1,614.50 | 1,553.40 | 1,526.40 | 1,509.35 | 1,482.35 |
EMA & SMA
1445.00
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
18
5 Day 1472.88
9 Day 1452.80
10 Day 1457.17
12 Day 1473.29
14 Day 1469.67
20 Day 1450.36
26 Day 1479.86
50 Day 1543.58
100 Day 1553.06
200 Day 1423.05
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| USHA MADHUKAR CHANDURKAR | bulk | Sell | 18 Dec, 2024 | ₹1,501.52 | 40,00,000 | BSE |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 25 Oct, 2022 | ₹900.35 | 68,372 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 25 Oct, 2022 | ₹900.35 | 1,48,105 | BSE |
| ISHARES MSCI INDIA SMALL-CAP ETF | block | Buy | 25 Oct, 2022 | ₹900.35 | 68,372 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 25 Oct, 2022 | ₹900.35 | 1,48,105 | BSE |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 17 Oct, 2022 | ₹889.45 | 34,160 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 17 Oct, 2022 | ₹889.45 | 2,32,725 | BSE |
| ISHARES MSCI INDIA SMALL-CAP ETF | block | Buy | 17 Oct, 2022 | ₹889.45 | 34,160 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 17 Oct, 2022 | ₹889.45 | 2,32,725 | BSE |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 11 Oct, 2022 | ₹912.05 | 25,053 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 11 Oct, 2022 | ₹912.05 | 1,70,676 | BSE |
| GOLDMAN SACHS INDIA FUND LIMITED | bulk | Sell | 02 Sept, 2021 | ₹2,531.90 | 9,27,874 | BSE |
| GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO | bulk | Buy | 02 Sept, 2021 | ₹2,531.90 | 9,27,874 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 19 Dec, 2024 | Mrs. Usha M. Chandurkar | Disposal | ₹1,499.245761 | 40,00,000 | BSE |
| 12 Mar, 2024 | Paschim Chemicals Pvt. Ltd. | Acquisition | ₹1,200.9654 | 35,000 | BSE |
| 20 Nov, 2023 | Mr. Ajit Kumar Jain | Disposal | ₹1,081.84665 | 20,000 | BSE |
| 19 Sept, 2022 | Mr. E. J. Babu Former Designated Employee | Disposal | ₹874.385 | 2,000 | BSE |
| 04 Aug, 2022 | Mrs. Usha Chandurkar | Acquisition | ₹ | 40,00,000 | BSE |
| 01 Aug, 2022 | Mrs. Usha Chandurkar | Acquisition | ₹ | 3,02,000 | BSE |
| 21 Mar, 2022 | Mr. A. K. Jain | Disposal | ₹1,026.81685 | 20,000 | BSE |
| 26 Aug, 2021 | Kavita Sehwani | Disposal | ₹2,441.157777777777777777777778 | 450 | BSE |
| 23 Aug, 2021 | Pabitra Kumar Bhattacharyya | Disposal | ₹2,510.00 | 4,000 | BSE |
| 19 Aug, 2021 | Ajit Kumar Jain | Disposal | ₹2,421.8979 | 10,000 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 24 Oct, 2024 | Rs.2.0000 per share(200%)Interim Dividend (Revised) | 25 Nov, 2024 | 25 Nov, 2024 |
| 29 May, 2024 | Rs.2.0000 per share(200%)Final Dividend | 06 Aug, 2024 | 01 Jan, 1970 |
| 26 Oct, 2023 | Rs.2.0000 per share(200%)Interim Dividend (Revised) | 22 Nov, 2023 | 22 Nov, 2023 |
| 13 Nov, 2021 | Stock split from Rs. 2/- to Re. 1/-. | 10 Jan, 2022 | 11 Jan, 2022 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 18 Feb, 2025 | NSE India | IPCA Laboratories Limited has informed the Exchange about transcript ofconference call which was held on Thursday, 13th February, 2025 to discuss theCompany s Q3 FY25 earnings and business update |
| 18 Feb, 2025 | BSE India | Transcript of conference call held on Thursday, 13th February, 2025 to discuss the Company's Q3 FY25 earnings and business update |
| 14 Feb, 2025 | NSE India | IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |
| 13 Feb, 2025 | NSE India | IPCA Laboratories Limited has informed the Exchange about Link of Recording |
| 13 Feb, 2025 | BSE India | Audio Link of Conference Call held on 13th February, 2025 |
| 13 Feb, 2025 | NSE India | Integrated Filing (Financial) |
| 13 Feb, 2025 | NSE India | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024. |
| 13 Feb, 2025 | NSE India | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2025. |
| 13 Feb, 2025 | BSE India | Standalone and Consolidated Q3FY25 Results |
| 13 Feb, 2025 | BSE India | Standalone and Consolidated Q3FY25 Results & Press Release |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 28 Jan, 2025 | 13 Feb, 2025 |
| Quarterly Results & Interim Dividend | -- | 25 Oct, 2024 | 14 Nov, 2024 |
| Others | -- | 25 Sept, 2024 | 30 Sept, 2024 |
| Quarterly Results | -- | 25 Jul, 2024 | 13 Aug, 2024 |
| Audited Results & Final Dividend | -- | 08 May, 2024 | 29 May, 2024 |
| Quarterly Results | -- | 24 Jan, 2024 | 14 Feb, 2024 |
| Quarterly Results & Interim Dividend | -- | 26 Oct, 2023 | 10 Nov, 2023 |
| Quarterly Results | -- | 24 Jul, 2023 | 10 Aug, 2023 |
| Audited Results | -- | 15 May, 2023 | 29 May, 2023 |
| Quarterly Results | -- | 23 Jan, 2023 | 14 Feb, 2023 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sept, 2023 |
|---|
About Ipca Laboratories
Ipca Laboratories is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 6166.46 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1949
Managing Director
Mr. Ajit Kumar Jain
NSE Symbol
IPCALAB
Ipca Laboratories Management
| Name | Designation |
|---|---|
| Mr. Premchand Godha | Executive Chairman |
| Mr. Ajit Kumar Jain | Managing Director |
| Mr. Pranay Godha | Managing Director |
| Mr. Prashant Godha | Executive Director |
| Dr.(Mrs.) Manisha Premnath | Independent Director |
| Mr. Kamal Kishore Seth | Independent Director |
| Dr. Narendra Mairpady | Independent Director |
| Dr.(Ms.) Swati Patankar | Independent Director |
| Mr. Vivek Shiralkar | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Ipca Laboratories
What is the share price of Ipca Laboratories?
The share price of Ipca Laboratories on 21 Feb, 2025 is ₹ 1,445.00.
What is 52W high and 52W low share price of Ipca Laboratories?
The highest and lowest 52W share prices of Ipca Laboratories are ₹ 1708.700 and ₹ 1057.200
What is the market cap of Ipca Laboratories?
The market capitalization of Ipca Laboratories as of 21 Feb, 2025 is ₹ 36,658.99 Crores
What is the P/E ratio of Ipca Laboratories?
The current P/E ratio of Ipca Laboratories as of 21 Feb, 2025 is 43.99
What is the PB ratio of Ipca Laboratories?
The PB ratio of Ipca Laboratories as of 21 Feb, 2025 is 4.74
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)